Yarrow Bioscience, Inc. Common Stock
YARW
41 hedge funds and large institutions have $5.63M invested in Yarrow Bioscience, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 16 closing their positions.
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
16% less funds holding
Funds holding: 49 → 41 (-8)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
55% less capital invested
Capital invested by funds: $12.5M → $5.63M (-$6.89M)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
+$92.1K |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
+$79K |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$49.3K |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$43.4K |
| 5 |
Renaissance Technologies
New York
|
+$39.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.22M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$506K |
| 3 |
State Street
Boston,
Massachusetts
|
-$225K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$169K |
| 5 |
Goldman Sachs
New York
|
-$118K |
YARW Hedge Fund Activity: Q1 2022 in Review
41 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q1 2022, worth a combined $5.63M — down 55% from $12.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of YARW and 8 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 4 added.
The largest buyer was Bailard, opening a new position worth an estimated $92.1K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.22M sold.
- 41 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q1 2022, down from 49 in Q4 2021.
- Funds reported $5.63M of Yarrow Bioscience, Inc. Common Stock stock for Q1 2022, down 55% quarter-over-quarter.
- 8 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q1 2022 and 16 closed out, a net change of -8 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q1 2022 was Bailard, an estimated $92.1K added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q1 2022 was Perceptive Advisors, an estimated $2.22M sold.
Based on aggregated 13F filings for Q1 2022.